45th week of 2010 patent applcation highlights part 34 |
Patent application number | Title | Published |
20100284894 | HOT SOLIDS PROCESS SELECTIVELY OPERABLE BASED ON ITS PRIMARY PURPOSE - A hot solids process selectively operable for purposes of generating at least one predetermined output based on what the specific nature of the primary purpose of the hot solids process is for which the at least one predetermined output that is selected from a multiplicity of predetermined outputs, such as H2 and CO2, is being produced, and wherein such primary purpose of the hot solids process is designed to be pre-selected from a group of primary purposes of the hot solids process that includes at least two of the generation of H2 for electric power purposes, the generation of SynGas for electric power production as well as for other industrial uses, the production of steam for electric power generation as well as for other uses, the production of process heat, the production of CO2 for agricultural purposes, and the generation of a feedstock such as H2 for use for the production of liquid hydrocarbons. | 2010-11-11 |
20100284895 | TANTALUM CARBIDE, METHOD FOR PRODUCING TANTALUM CARBIDE, TANTALUM CARBIDE WIRING AND TANTALUM CARBIDE ELECTRODE - It is an object of the present invention to provide a method for manufacturing tantalum carbide which can form tantalum carbide having a prescribed shape using a simple method, can form the tantalum carbide having a uniform thickness even when the tantalum carbide is coated on the surface of an article and is not peeled off by a thermal history, tantalum carbide obtained by the manufacturing method, wiring of tantalum carbide, and electrodes of tantalum carbide. | 2010-11-11 |
20100284896 | Increasing the specific strength of spun carbon nanotube fibers - A spun fiber of carbon nanotubes is exposed to ion irradiation. The irradiation exposure increases the specific strength of the spun fiber. | 2010-11-11 |
20100284897 | Apparatus and method for synthesizing carbon nanotube - An apparatus for synthesizing a carbon nanotube includes a reaction chamber, a cassette, a transferring member, a heater, a gas supply member and a gas exhausting part. The carbon nanotube is synthesized in the reaction chamber. The reaction chamber has a substantially vertical major axis. The cassette holds a plurality of substrates. The transferring member transfers the cassette along a direction substantially in parallel relative to the major axis to load/unload the cassette into/from the reaction chamber. The heater heats the reaction chamber. The gas supply member provides the reaction chamber with a gas for synthesizing the carbon nanotube. The gas exhausting member exhausts a remaining gas from the reaction chamber. Collecting the carbon nanotube may be facilitated and managing the reaction chamber may be effective to enhance a productivity of the carbon nanotube. | 2010-11-11 |
20100284898 | BULK CUTTING OF CARBON NANOTUBES USING ELECTRON BEAM IRRADIATION - According to some embodiments, the present invention provides a method for attaining short carbon nanotubes utilizing electron beam irradiation, for example, of a carbon nanotube sample. The sample may be pretreated, for example by oxonation. The pretreatment may introduce defects to the sidewalls of the nanotubes. The method is shown to produces nanotubes with a distribution of lengths, with the majority of lengths shorter than 100 tun. Further, the median length of the nanotubes is between about 20 nm and about 100 nm. | 2010-11-11 |
20100284899 | GENERATION OF SULFUR TRIOXIDE AND SULFURIC ACID - Configurations herein include a novel process and apparatus for generating and maintaining sulfur trioxide gas. The generation system and process operate to provide sulfur trioxide calibration gas for calibrating sulfur trioxide detection devices. The system and process provides a known, concentration of sulfur trioxide gas via a heated catalyst, which enables accurate calibration of measurement equipment. The system functions in part by controlling temperature, amount of moisture, residence time, catalyst selection, diluting generated sulfur trioxide and by locating the sulfur trioxide generator at a point of injection of a sulfur trioxide detection system. | 2010-11-11 |
20100284900 | METHOD FOR RECOVERING SULFURIC ACID FROM CONCENTRATED ACID HYDROLYSATE OF PLANT CELLULOSE MATERIAL - A method for recovering sulfuric acid from concentrated acid hydrolysate of plant cellulose material is disclosed. In some of the examples, the concentrated acid hydrolysate is mixed with a liquid organic precipitant, thereby the sugars in the hydrolysate is precipitated and separated out, and the remained is sulfuric acid and an organic solvent solution. Then the organic solvent is separated by distillation or extraction, thereby obtaining the pure sulfuric acid solution. This precipitation method can recover above 90% sugars and acids with a small amount of organic precipitant, which greatly reduces the recover cost. In the other examples, the method includes: mixing the concentrated acid hydrolysate with a water-immiscible alcohol, thereby separating the sugars with a remainder of acid-alcohol solution containing sulfuric acid; contacting the acid-alcohol solution with water, thereby the sulfuric acid enters into the water phase from the organic phase; then separating the organic phase and the water phase, thereby obtaining the sulfuric acid solution. This method avoids the use of poisonous, inflammable and explosive organic solvents and also avoids the energy consumption for recovering these organic solvents, thereby greatly reducing the cost of acid recovery. | 2010-11-11 |
20100284901 | METHOD AND COMPOSITION FOR PREPARATION OF HYDROGEN PEROXIDE - The present invention relates to a method for the preparation of hydrogen peroxide through a continuous process, extracting hydrogen peroxide produced from reduction and oxidation of a working solution and recycling the oxidized working solution back to the reduction process, wherein the composition of the working solution, i.e. the composition of 2-alkylanthraquinone and 2-tetrahydroalkylanthraquinone, is optimized to increase the solubility of the quinones and to improve the reaction rate. The working solution comprises 2-alkylanthraquinone, 2-tetrahydroalkylanthraquinone and an organic solvent, wherein 65-95 mol % of the alkyl group of 2-alkylanthraquinone and 2-tetrahydroalkylanthraquinone is amyl and the remaining 5-35 mol % of the alkyl group is ethyl, and the molar ratio of 2-alkylanthraquinone to 2-tetrahydroalkylanthraquinone is from 4:6 to 1:9. | 2010-11-11 |
20100284902 | Continuous process for the preparation of sodium titanate nanotubes - The invention relates to a continuous process for the preparation of sodium titanate nanotubes and their derivatives obtained by ion exchange and/or thermal treatment, by reacting titanium oxides with sodium hydroxide under suitable hydrothermal conditions to obtain or control the morphology of nanostructural titanates. | 2010-11-11 |
20100284903 | New Class of Tunable Gas Storage and Sensor Materials - The electronic structure of nanowires, nanotubes and thin films deposited on a substrate is varied by doping with electrons or holes. The electronic structure can then be tuned by varying the support material or by applying a gate voltage. The electronic structure can be controlled to absorb a gas, store a gas, or release a gas, such as hydrogen, oxygen, ammonia, carbon dioxide, and the like. | 2010-11-11 |
20100284904 | METHODS AND SYSTEMS FOR GENERATING HYDROGEN AND SEPARATING CARBON DIOXIDE - Methods and systems for generating hydrogen and separating carbon dioxide from a feed stream including hydro-carbons and water are disclosed. In some embodiments, the method includes the following: providing a catalytic chamber including a monolithic structure having surfaces coated with carbon dioxide adsorbing materials and one or more washcoated layers of combined steam reforming, water gas shift, and combustion catalysts; directing the feed stream into said catalytic chamber; controlling the feed stream so that it has a temperature range that allows the reactive generation of carbon dioxide and hydrogen gas but does not cause substantial development of coke between hydrocarbons in the feed stream and said surfaces of said monolithic structure; and adsorbing said carbon dioxide generated by heating the feed stream, wherein said carbon dioxide is adsorbed onto carbon dioxide adsorbing materials on said surfaces of said monolithic structure. | 2010-11-11 |
20100284905 | Methods and Agents for Inhibiting Tumor Growth by Targeting the SSDNA Replication Intermediate of Tumor Stem Cells - The application is based on the observation that tumor stem cell (TSC) replication involves a replicative intermediate configuration wherein a substantial fraction of the TSC genome is present as single-stranded DNA (ssDNA) when bell-shaped nuclei commence separation into two nuclei. During this replicative intermediate configuration large amounts of ssDNA are thus present in the nuclei of cells which the applicant proposes as target for anti-tumor therapy. A method of screening for anti-tumorigenic agents targeting ssDNA and use of such agents in therapy is claimed. | 2010-11-11 |
20100284906 | Internalizing Anti-CD74 Antibodies and Methods of Use - The present invention provides humanized, chimeric and human anti-CD74 antibodies, CD74 antibody fusion proteins, immunoconjugates, vaccines and bispecific that bind to CD74, the major histocompatibility complex (MHC) class-II invariant chain, Ii, which is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies, other malignancies in which the cells are reactive with CD74, and autoimmune diseases, and methods of treatment and diagnosis. | 2010-11-11 |
20100284907 | TREATMENT OF TUMORS BY ABLATING BONE MARROW-DERIVED ENDOTHELIAL PROGENITOR CELLS - This invention provides methods of treating tumors and other conditions characterized by abnormal neoangiogenesis by inhibiting bone marrow-derived endothelial progenitor cells. | 2010-11-11 |
20100284908 | PROTEINS - The present invention provides new polypeptides. Said polypeptides are of use in the screening, diagnosis and prognosis of B-cell non-Hodgkin's lymphoma, breast cancer, colorectal cancer, gastric cancer, hepatocellular carcinoma, lung cancer, lymphoid leukaemia (particularly acute T-cell leukaemia), melanoma, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer and renal cell cancer, in monitoring the effectiveness of B-cell non-Hodgkin's lymphoma, breast cancer, colorectal cancer, gastric cancer, hepatocellular carcinoma, lung cancer, lymphoid leukaemia (particularly acute T-cell leukaemia), melanoma, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer and renal cell cancer treatment, and in drug development. Also provided are antibodies (and other affinity reagents such as Affibodies) which interact with or modulate the expression or activity of the polypeptides. | 2010-11-11 |
20100284909 | IMMUNOTHERAPY TARGETING OF THE SHARED ABNORMAL CONFORMATIONAL STATE OF AMYLOIDOGENIC PEPTIDES/PROTEINS - The present invention is directed to pharmaceutical agents and compositions useful for the treatment and prevention of amyloid disease in a subject. The invention further relates to isolated antibodies that recognize a common conformational epitope of amyloidogenic proteins or peptides that are useful for the diagnosis, treatment, and prevention of amyloid disease. | 2010-11-11 |
20100284910 | Novel Method of Diagnosing, Monitoring, Staging, Imaging and Treating Various Cancers - The present invention provides a new method for detecting, diagnosing, monitoring, staging, prognosticating, imaging and treating selected cancers including gynecologic cancers such as breast, ovarian, uterine and endometrial cancer and lung cancer. | 2010-11-11 |
20100284911 | PREPARATIONS AND METHODS FOR TREATING MALIGNANCIES - Disclosed are therapeutic formulations comprising antibodies for the monomeric isoform of A-protein and a physiologically acceptable carrier. Methods for the treatment of subjects using these therapeutic formulations are also disclosed. | 2010-11-11 |
20100284912 | HOMOGENIZATION OF A RADIOPHARMACEUTICAL USING SONIFICATION AND/OR ROTOR-STATOR TECHNOLOGY TO PRODUCE A HOMOGENOUS SUSPENSION, EMULSION, MIXTURE OR SOLID SUSPENSION OF IMMISCIBLE INGREDIENTS - A homogenous dispersion of aqueous droplets of a radiopharmaceutical or radiodiagnostic agent within a non-aqueous medium and method of making the same is provided. The homogenous dispersion is largely free of impurities and constitutes a substantially uniform distribution of sodium thiosulfate and radiopharmaceutical which is stable for a time sufficient to fill and solidify within gel capsules. In making the homogenous dispersion, dry sodium thiosulfate and dry potassium phosphate dibasic anhydrous are uniformly dispersed within non-aqueous, liquid polyethylene glycol. | 2010-11-11 |
20100284913 | Methods and compositions for studying, imaging, and treating pain - Saxitoxin analogue compounds, compositions, pharmaceutical compositions, methods of synthesis of saxitoxin analogues, methods of imaging, methods of treatment, including methods of treating pain, are provided. Saxitoxin (STX), gonyautoxin (GTX), and zetekitoxin, and variant STX compounds bind to sodium channels and are effective to reduce or block flow of sodium ions through such channels. Such channel block affects nerve and muscle action, and may be effective to reduce or block pain sensations, relax muscles, reduce muscle spasm, and reduce wrinkles. STX analogue binding to sodium channels may also be useful to locate, image, or mark sodium channels, and so be useful in studying sodium channels and sodium channel disorders, and in the diagnosis and treatment of patients suffering from sodium channel disorders. In embodiments, the variant STX compounds include conjugates having increased serum half-life as compared to STX when administered to a subject. | 2010-11-11 |
20100284914 | Novel Amine-Borane Compounds and Uses Thereof - Novel families of amine-borane compounds, including fluorinated aminoboranes, novel bis-aminoboranes and aminoboranes having saturated and unsaturated ling alkyl chains are provided. Processes of preparing, pharmaceutical compositions and methods utilizing these novel compounds are also provided. Radiolabeled aminoboranes and uses thereof in radioimaging (e.g., PET) and radiotherapy are further provided. | 2010-11-11 |
20100284915 | GENES ASSOCIATED WITH CHEMOTHERAPY RESPONSE AND USES THEREOF - The invention provides molecular markers that are associated with responsiveness of a cancer patient to a chemotherapy treatment, and methods and computer systems for determining such responsiveness based on measurements of these molecular markers. The present invention also provides methods and compositions for enhancing the efficacy of chemotherapies in patients by modulating the expression or activity of genes encoding these molecular markers and/or their encoded proteins. | 2010-11-11 |
20100284916 | Antibodies Against Human Cytomegalovirus (HCMV) - The present invention provides novel antibody sequences that bind human cytomegalovirus (hCMV) and neutralize hCMV infection. The novel sequences can be used for the medical management of hCMV infections, in particular for preparing pharmaceutical compositions to be used in the prophylactic or therapeutic treatment of hCMV infections. | 2010-11-11 |
20100284917 | COMPOUNDS AND MARKERS FOR SURFACE-ENHANCED RAMAN SCATTERING - The present invention relates to compounds and markers for surface-enhanced Raman scattering (SERS), and methods for the preparation of the SERS markers. The present invention further relates to compositions, methods and uses, wherein the present SERS markers are employed. | 2010-11-11 |
20100284918 | PROTEIN - The present invention provides methods and compositions for treatment, screening, diagnosis and prognosis of breast cancer, colorectal cancer, gastric cancer, hepatocellular carcinoma, lung cancer and pancreatic cancer, for monitoring the effectiveness of breast cancer, colorectal cancer, gastric cancer, hepatocellular carcinoma, lung cancer and pancreatic cancer treatment, and for drug development. | 2010-11-11 |
20100284919 | Injectable Radio-Opaque Compositions for Tissue Augmentation - Injectable radio-opaque compositions for tissue augmentation and in particular hard tissue augmentation, and kits and methods of using thereof are described herein. The injectable compositions form porous, biologically degradable, fibrin matrices. The compositions are formed from fibrinogen, thrombin or another agent that causes the fibrinogen to crosslink, and strontium salts. Optionally an iodinated contrast agent is further incorporated in the composition. In certain aspects, the compositions have substantially no exothermicity when forming the matrix and the resulting matrices exhibit mechanical properties typically seen in elastomers. Adequate radio-opacity is achieved through the incorporation of strontium salts in combination or not with iodinated contrast agents. | 2010-11-11 |
20100284920 | USES OF MONOCLONAL ANTIBODY 8H9 - This invention provides a composition comprising an effective amount of monoclonal antibody 8H9 or a derivative thereof and a suitable carrier. This invention provides a pharmaceutical composition comprising an effective amount of monoclonal antibody 8H9 or a derivative thereof and a pharmaceutically acceptable carrier. This invention also provides an antibody other than the monoclonal antibody 8H9 comprising the complementary determining regions of monoclonal antibody 8H9 or a derivative thereof, capable of binding to the same antigen as the monoclonal antibody 8H9. This invention provides a substance capable of competitively inhibiting the binding of monoclonal antibody 8H9. This invention also provides an isolated scFv of monoclonal antibody 8H9 or a derivative thereof. This invention also provides the 8H9 antigen. This invention also provides different uses of the monoclonal antibody 8H9 or its derivative. | 2010-11-11 |
20100284921 | TARGETED NANOPARTICLES FOR INTRACELLULAR CANCER THERAPY - This invention provides constructs comprising a targeting member immobilized on a detectable particulate, in which binding of the targeting member to a target structure on a surface of a cancer cell triggers internalization of the construct. Such constructs can be used to identify or monitor cancer cells in cell cultures or in a tissue. Such construct can also be used to kill or prevent growth of cancer cells in vivo. Also included in the invention are methods for killing or preventing growth of cancer cells in vivo. | 2010-11-11 |
20100284922 | MARKER - The invention relates to the use of a cell death marker labelled with a wavelength-optimised label for identifying cell death in the eye. Suitable cell death markers are the Annexins and fragments and derivatives thereof. The invention also relates to a pharmaceutical composition comprising a cell death marker labelled with a wavelength-optimised label and a method for monitoring cell death in the eye using a cell death marker labelled with a wavelength-optimised label. | 2010-11-11 |
20100284923 | METHODS OF DIAGNOSING LATENT AND ACTIVE MALIGNANCIES - Disclosed are procedures and methods for diagnosing latent and active cancers in a subject. The described methods include the use of sandwich ELISA assays containing antibodies specific for certain epitopes on the A-protein. This enables the assay to discriminate between the monomelic and homopolymeric forms of A-protein. | 2010-11-11 |
20100284924 | NANO-DEVICES HAVING IMPELLERS FOR CAPTURE AND RELEASE OF MOLECULES - A nanodevice has a containment vessel defining a storage chamber therein and defining at least one port to provide transfer of molecules to or from the storage chamber, and a plurality of impellers attached to the containment vessel. The plurality of impellers are of a structure and are arranged to substantially block molecules from entering and exiting the storage chamber of the containment vessel when the impellers are static and are operable to impart motion to the molecules to cause the molecules to at least one of enter into or exit from the storage chamber of the containment vessel. | 2010-11-11 |
20100284925 | Small Molecule Intervention for Obesity - Methods and compositions for activating PLTP gene expression include administering an effective amount of a limonoid. | 2010-11-11 |
20100284926 | USE OF G-CSF FOR THE TREATMENT OF STROKE - The invention relates to the use of G-CSF for the treatment of cerebral stroke, particularly cerebral stroke with a large baseline infarct volume. Administration of G-CSF at a total dose of 30 to 180 μg per kg body weight over a treatment period of about 3 days is suitable for the treatment of stroke. Treatment in accordance with the invention with a total dose of 80 to 150 μg per kg body weight is preferred. | 2010-11-11 |
20100284927 | USE OF MRI CONTRAST AGENTS FOR EVALUATING THE TREATMENT OF TUMORS - Described herein are methods for using macromolecular MRI contrast agents to evaluate the effectiveness of anti-cancer treatments. The methods take advantage of MRI for evaluating more specifically and accurately one or more tumor properties of the tumor in response to a particular treatment. Ultimately, the 5 methods described herein help evaluate the effectiveness of the anti-cancer treatment over time. | 2010-11-11 |
20100284928 | METHODS FOR IN VIVO ATHEROSCLEROTIC PLAQUE CHARACTERIZATION USING MAGNETIC SUSCEPTIBILITY TO IDENTIFY SYMPTOM-PRODUCING PLAQUES - Methods and uses of in vivo atherosclerotic plaque characterization in a subject in need thereof, that include detecting a level of one or more iron complexes in plaque in the subject, and comparing detected level to a known value determined from subjects without an atherosclerotic condition are disclosed. | 2010-11-11 |
20100284929 | FLUORESCENT IMAGING OF TUMORS USING PHOSPHOLIPID ETHER COMPOUNDS - The invention generally relates to the use of novel fluorescent phospholipid ether compounds and compositions comprising these compounds in fluorescence imaging of tumors. A preferred compound of the present invention has the following structural formula: | 2010-11-11 |
20100284930 | FLUORESCENT IMAGING OF SKIN CANCERS USING PHOSPHOLIPID ETHER COMPOUNDS - The invention generally relates to novel fluorescent phospholipid compounds, compositions comprising these compounds, and their use in a variety of diagnostic applications, including fluorescence imaging of tumors. A preferred compound of the present invention has the following structural formula: | 2010-11-11 |
20100284931 | FLUORESCENT PHOSPHOLIPID ETHER COMPOUNDS, COMPOSITIONS, AND METHODS OF USE - The invention generally relates to novel fluorescent phospholipid compounds, compositions comprising these compounds, and their use in a variety of diagnostic applications, including fluorescence imaging of tumors. A preferred compound of the present invention has the following structural formula: | 2010-11-11 |
20100284932 | FLUORESCENT EMULSIONS FOR OPTICAL IMAGING - The invention relates to a fluorescent emulsion, to a diagnostic reagent containing the same, and to the use thereof in the preparation of a diagnostic reagent for in vivo fluorescence imaging. | 2010-11-11 |
20100284933 | Biomarkers of Multiple Sclerosis - Biomarkers of multiple sclerosis (MS) and of anti-TWEAK/TWEAK-Receptor therapy for MS are described. | 2010-11-11 |
20100284934 | DIAGNOSTIC AGENT - The invention provides an agent comprising an amino acid sequence for use in a method of diagnosis of a synucleinopathic disease. | 2010-11-11 |
20100284935 | MARKERS AND DIAGNOSTIC METHODS FOR METASTASIS - The present invention provides methods for the prediction, prognosis and/or diagnosis of metastasis. The present invention also provides proteins (or the related nucleic acid sequences) or protein expression profiles which are predictive and/or prognostic for metastasis. The invention thus relates to the use of said proteins and the corresponding amino acid or nucleic acid sequences for the prediction, prognosis or diagnosis of metastasis. | 2010-11-11 |
20100284936 | CONTRAST AGENTS - The present invention relates to liposomes comprising particles with cores of tungsten or tungsten in mixture with other metallic elements as the contrast enhancing material and to the use of such pharmaceuticals, specifically as contrast agents in diagnostic imaging and in particular in X-ray imaging of liver tumours. | 2010-11-11 |
20100284937 | VAGINAL LUBRICANT COMPRISING HYALURONIC ACID - A vaginal lubricant comprising high molecular weight hyaluronic acid combined with low molecular weight hyaluronic acid and/or chitosan which has improved stability and which has applications in, for example, maintaining and/or promoting sperm motility. | 2010-11-11 |
20100284938 | PENETRATING PHARMACEUTICAL FOAM - The invention relates to an alcohol-free cosmetic or pharmaceutical foam composition comprising water, a hydrophobic solvent, a surface-active agent, a gelling agent, an active component selected from the group of urea, hydroxy acid and a therapeutic enhancer and a propellant. The foam further comprises active agents and excipients with therapeutic properties having enhanced skin penetration. | 2010-11-11 |
20100284939 | HAIR CARE COMPOSITIONS AND METHODS OF TREATING HAIR USING SAME - The present invention provides kits and methods for treating hair on the scalp comprising non-toxic compositions providing beneficial effects on hair without employing high temperatures, free radical initiators or rinsing hair after applying the compositions. | 2010-11-11 |
20100284940 | METHOD OF THERAPEUTIC ADMINISTRATION OF DHE TO ENABLE RAPID RELIEF OF MIGRAINE WHILE MINIMIZING SIDE EFFECT PROFILE - Pharmaceutical compositions containing dihydroergotamine (DHE) and methods in which DHE is administered to patients for treatment of migraine without side effects or adverse effects are disclosed. Methods for rapid treatment of migraine with DHE are disclosed comprising: dampening the peak plasma concentration (C | 2010-11-11 |
20100284941 | Hair Treatment Composition Comprising a Pressure Sensitive Adhesive - A hair treatment composition comprising an acrylic pressure sensitive adhesive. | 2010-11-11 |
20100284942 | Compositions - There are provided personal care products and compositions that comprise at least one diol compound selected from the group consisting of 1,2-pentanediol, 1,2-hexanediol, 1,2-octanediol, 2-methyl-1,3-propandiol, and 3-(2-ethyl-hexyloxy)-1,2-propandiol in a total concentration of 0.1% to 0.5% (w/w); and at least one preservative enhancer compound selected from the group consisting of benzaldehyde, 4-methylbenzaldehyde, heliotropine, vanilline, 4-hydroxybenzaldehyde, 3-hydroxybenzaldehyde, 4-methoxybenzaldehyde and 3-methoxybenzaldehyde, 2,4-dihydroxybenzaldehyde, 3-hydroxy-4-methoxybenzaldehyde, 3,5-dihydroxybenzaldehyde, and 4-hydroxy-2-methoxybenzaldehyde, in a total concentration of 0.05 to 0.5% (w/w), in a cosmetically acceptable base. The composition optionally contains at least one compound selected from the group consisting of phenoxyethanol, 2-phenylethanol, and benzylalcohol, in a total concentration of 0.05 to 0.3% (w/w), but does not contain other classic bactericidal, fungicidal, sporicidal or preservative compounds. The invention is further directed to methods of forming such compositions and products and the use of preservatives and preservative enhancers in such compositions and products. | 2010-11-11 |
20100284943 | Active Formulations Based on Plant Extracts; Phytocosmetic and/or Phytotherapeutic Formulations Comprising the Same Method For - The present invention provide formulations with antibacterial and biofilm removing actions comprising plant extracts, comprising at least one plant oil wherein the plant is selected from the group comprising the genus | 2010-11-11 |
20100284944 | OFF-NOTE BLOCKING SENSORY ORGANIC COMPOUNDS - Disclosed are Compounds that block off-notes in consumables and methods of blocking off-notes in consumables including off-notes provided by artificial sweeteners including aspartame, Saccharin, acesulfame K (Acesulfame potassium), sucralose and cyclamate; and including stevioside, swingle extract, glyccerhizin, perillartine, naringin dihydrochalcone, neohesperidine dihydrochalcone, mogroside V, rubusoside, rubus extract, and rebaudioside A. | 2010-11-11 |
20100284945 | FORMULATIONS FOR THE TREATMENT OF MUCOSITIS INDUCED BY ANTITUMOR OR IMMUNOSUPPRESSIVE THERAPY - Formulations containing sanguinarine or chelerythrine or the salts thereof or extracts containing them in admixture with suitable carriers and/or excipients for the treatment and/or prevention of mucositis. | 2010-11-11 |
20100284946 | Compressed Chewing Gum Comprising Sterol - A compressed chewing gum tablet including at least one chewing gum module, the chewing gum module including a chewing gum composition including chewing gum particles containing gum base, wherein the chewing gum tablet includes at least one sterol compound, and wherein at least a part of the at least one sterol compound is located outside the chewing gum particles containing gum base. | 2010-11-11 |
20100284947 | Food Product to Prevent Tooth Decay - An anti cavity bioconsumable liquid which may be provided in the liquid form or frozen form is disclosed herein. The liquid may include up to about 5 wt. % xylitol for the purposes of mitigating tooth decay when the bioconsumable liquid is ingested or consumed by a person. Moreover, the bioconsumable liquid may include up to about 5 wt. % of dextrose but never more than the wt. % of xylitol for the purposes of sweetening the bioconsumable liquid to retain an acceptable flavor profile. An infant, child or adult may consume the bioconsumable liquid during which the xylitol acts to mitigate tooth decay. The bioconsumable liquid may also be frozen in an ice pop configuration and consumed by a child or an adult. The ice pop retains an acceptable flavor profile and also mitigates tooth decay. | 2010-11-11 |
20100284948 | O/W-EMULSIFIERS, O/W-EMULSIONS AND METHODS OF MANUFACTURE THEREOF - O/W-emulsifiers are described, comprising:
| 2010-11-11 |
20100284949 | Water-Containing Composition Which Can Be Used As External Composition - An object of the present invention is to provide means for enhancing ability to solubilize a low water-soluble substance or to disperse the substance in water. The present invention provides a water-containing composition containing water; at least one polyoxyethylene-polyoxypropylene-added phytosterol or phytostanol represented by the following formula (1): | 2010-11-11 |
20100284950 | WATER BASED CONCENTRATED PRODUCT FORMS OF OIL-SOLUBLE ORGANIC UV ABSORBERS - The instant invention refers to the use of a concentrated aqueous polymer dispersion with an average particle size of less than 1000 nm comprising (a) a polymer carrier prepared by heterophase radical polymerization of at least one ethylenically unsaturated monomer in the presence of (b) an oil-soluble organic UV absorber selected from the class of p-aminobenzoic acid derivatives; salicylic acid derivatives; benzophenone derivatives; diphenyl acrylate derivatives; benzofuran derivatives; polymeric UV absorbers, comprising one or more organosilicon radicals; cinnamic acid derivatives; camphor derivatives; s-triazine derivatives; trianilino-s-triazine derivatives; menthyl anthranilates; and benzotriazole derivatives; wherein the weight ratio of the oil-soluble organic UV absorber (b) to polymer carrier (a) is greater than 50 parts UV absorber per 100 parts of carrier; for the protection of human and animal hair and skin against the damaging effect of UV radiation. The concentrated aqueous polymer dispersions show unexpectedly high sunscreen effects and a positive skin feeling. | 2010-11-11 |
20100284951 | Novel compositions for the treatment of wounds and skin care - The present invention provides novel compositions which comprise sodium hypochlorite, sodium, chloride, both organic and inorganic trace minerals in hypertonic condition presented in the forms of a clear aqueous solution (low or high concentrations for further reconstitution with purified water to obtain the final ready-to-use solution), gel or salve, lotion, wet pad, wet foam, ointment, stick, and dry mixture solution, for local application for the purposes of cleansing, disinfecting and inhibiting infection and promoting the natural healing of conditions such as fresh cuts, surgical stitches, chronic (diabetic gangrene) and acute wounds, herpes zoster, athlete's foot, and bed sores, without the necessity for covering up the wounds with gauzes/plasters nor any concurrent use of topical medication. These compositions are also suitable for the treatment of conditions such as unpleasant body odor, acne and mixed bacterial infection in the ear. | 2010-11-11 |
20100284952 | Hair Treatment Compositions - The invention provides a hair treatment composition comprising a combination of a sugar, an aliphatic amino acid and a basic amino acid. The composition is particularly suitable for the treatment of hair which is dry, damaged and/or prone to manageability problems. | 2010-11-11 |
20100284953 | HAIR CARE COMPOSITIONS AND METHODS OF TREATING HAIR USING SAME - The present invention provides kits and methods for treating hair on the scalp comprising non-toxic compositions providing beneficial effects on hair without employing high temperatures, free radical initiators or rinsing hair after applying the compositions. | 2010-11-11 |
20100284954 | PROCESS FOR RELAXING KERATIN FIBRES - The invention relates to a process for relaxing keratin fibres by applying to the keratin fibres a relaxing composition containing at least one denaturing agent with a molecular mass of greater than 18.1 g/mol, present in a molar concentration of between 1M and 8M, and raising the temperature of the keratin fibres to a temperature of between 110 and 250° C. | 2010-11-11 |
20100284955 | Cationic Polymers And Fixative Applications Therefor - This invention relates to cationic | 2010-11-11 |
20100284956 | HAIR COSMETIC COMPOSITION - A hair cosmetic composition is provided wherein the hair cosmetic composition contains (a) a tertiary amine represented by general formula (1) below, (b) pyrrolidonecarboxylic acid, and (c) a higher alcohol. | 2010-11-11 |
20100284957 | Powder Treated with (Meth)Acrylic-Grafted Silicone Polymer and Product Using the Same - A powder treated with a (meth)acrylic-grafted silicone polymer, the treated powder being obtained from a mixture containing a volatile silicone oil, a (meth)acrylic-grafted silicone polymer in which a monomer component comprising a (meth)acrylic series monomer has been grafted onto the main chain of a polysiloxane, and a powder. | 2010-11-11 |
20100284958 | BoNT/A Peptides and Methods of Predicting and Reducing Immunoresistance to Botulinum Toxin Therapy - The present invention provides BoNT/A peptides as well as methods of predicting or determining immunoresistance to botulinum toxin therapy in an individual using BoNT/A peptides. | 2010-11-11 |
20100284959 | SEQUENCE SPECIFIC DOUBLE-STRANDED DNA/RNA BINDING COMPOUNDS AND USES THEREOF - The present invention provides specific double-stranded DNA/RNA binding compounds having a polymeric structure, which are in fact, triplex forming molecules capable of binding tightly and specifically to predetermined sequences in the major groove of double stranded nucleic acid molecules; as well as pharmaceutical compositions comprising thereof. The triplex forming molecules and the pharmaceutical compositions of the invention can be used for various therapeutic applications such as site-specific modulation of gene expression and targeting of DNA or RNA damage, as well as for diagnostic applications in vitro. | 2010-11-11 |
20100284961 | MCP-1 binding nucleic acids - The present invention is related to a nucleic acid, preferably binding to MCP-1, selected from the group comprising type 1A nucleic acids, type 1B nucleic acids, type 2 nucleic acids, type 3 nucleic acids, type 4 nucleic acids and nucleic acids having a nucleic acid sequence according to any of SEQ. ID. No. 87 to 115. | 2010-11-11 |
20100284962 | MODIFIED TUMOR NECROSIS FACTOR-BETA - Compositions including modified TNF-beta polypeptides and methods of using the compositions are disclosed herein. | 2010-11-11 |
20100284963 | GROWTH REGULATABLE RECOMBINANT BCG IMMUNOGENIC COMPOSITIONS - Immunogenic compositions comprising growth regulatable recombinant intracellular pathogens that have been transformed to express recombinant immunogenic antigens of the same or other intracellular pathogens are provided. Exemplary immunogenic compositions include, but are not limited to, growth regulatable and growth limited recombinant intracellular pathogen immunogenic compositions. | 2010-11-11 |
20100284964 | CANCER THERAPY - The subject invention provides for cancer therapy. | 2010-11-11 |
20100284965 | COMPOSITIONS AND METHODS FOR ADOPTIVE AND ACTIVE IMMUNOTHERAPY - Modular aAPCs and methods of their manufacture and use are provided. The modular aAPCs are constructed from polymeric microparticles. The aAPCs include encapsulated cytokines and coupling agents which modularly couple functional elements including T cell receptor activators, co-stimulatory molecules and adhesion molecules to the particle. The ability of these aAPCs to release cytokines in a controlled manner, coupled with their modular nature and ease of ligand attachment, results in an ideal, tunable APC capable of stimulating and expanding primary T cells. | 2010-11-11 |
20100284966 | Methods and Compositions for Managing Resistance of Hepatitis C Virus to Immunosuppressant - Method for determining susceptibility of a hepatitis C virus (HCV) in a patient, especially one who received a liver transplant, to cyclosporine A (CsA), comprising determining the nucleic acid sequence of HCV, and comparing the viral nucleic acid sequence to that of a wild-type, CsA susceptible strain, wherein the existence of at least one mutation in the viral genome is indicative that the virus is resistant to CsA. Also provided are isolated polynucleotide molecules comprising one or more mutations, an array of such molecules, a kit comprising at least one isolated polynucleotide. A method of monitoring the development CsA resistance in a HCV patient, and managing treatment regimens accordingly is further provided. The present invention further provides CsA resistant HCV replicons and method of using them for anti-viral drug screening. | 2010-11-11 |
20100284967 | MODIFIED PHAGE FOR DISPLAYING POST-TRANSLATIONALLY MODIFIED PROTEINS AND USES THEREOF - Disclosed herein are modified phage comprising a fusion protein located on the surface of the phage wherein the fusion protein comprises a surface protein and a post-translationally modified protein. Also disclosed are methods of making and using modified phage comprising post-translationally modified proteins located on the surface of the phage. | 2010-11-11 |
20100284968 | Use of PS20/WFDC1 and Interferons to Diagnose, Monitor and Treat Viral Diseases - Methods for detecting, diagnosing or monitoring viral diseases in a subject are described comprising measuring ps20 polypeptides or ps20 polynucleotides and interferons and interferon polynucleotides in a sample from the subject. The invention also contemplates therapeutic applications for viral diseases employing modulators of ps20 polypeptides and ps20 polynucleotides in combination with interferon or interferon polynucleotides. | 2010-11-11 |
20100284969 | Methods and Compositions for Delivery of Medicaments to the Lungs - The disclosure provides a drug composition formulated for inhalation comprising a conjugate of a surface active agent and a pulmonary active drug. The surface active agent has an affinity for the human alveolar/gas interface and comprises at least a portion of a mammalian lung surfactant of a mimic thereof. The disclosure also provides a method of treating a subject suffering from or at risk of suffering from a lung disease comprising administering to the subject a conjugate comprising a drug for lung treatment and a surface active agent by inhalation in an amount effective to induce a drug effect in the lungs. | 2010-11-11 |
20100284970 | BENZIMIDAZOLE MODULATORS OF H1 RECEPTOR AND/OR NS4B PROTEIN - The present invention relates to new benzimidazole modulators of H1 receptor activity and/or inhibitors of NS4B protein activity, pharmaceutical compositions thereof, and methods of use thereof. | 2010-11-11 |
20100284971 | MODIFIED FACTOR VIII AND FACTOR IX GENES AND VECTORS FOR GENE THERAPY - The present invention relates to a modified and optimized Factor VIII or Factor IX nucleic acid for inclusion in a chimeric virus vector. Use of such vector can be used for treatment of hemophilia. | 2010-11-11 |
20100284972 | COMPOSITIONS AND METHODS FOR MAKING ALPHA-(1,2)-BRANCHED ALPHA-(1,6) OLIGODEXTRANS - Compositions for improving the health of a subject comprise alpha-(1,2)-branched alpha-(1,6) oligodextrans, preferably with an average molecular weight between about 10 kDa and 70 kDa, between about 10% and 50% alpha-(1,2)-osidic side chains, and having at least partial indigestibility in the subject. Methods for improving the health of a subject comprise administering the composition to a subject in an amount effective to improve gut health, or to prevent or treat a gastrointestinal disorder, a cholesterol-related disorder, diabetes, or obesity. Methods for making oligodextrans having controlled size and controlled degree of branching comprise providing alpha-(1,6) oligodextrans having an average molecular weight between 0.5 and 100 kDa and introducing at least 10% alpha-(1,2)-osidic side chains onto the alpha-(1,6) oligodextrans. | 2010-11-11 |
20100284973 | Use of a L. Casei Strain For the Preparation of a Composition for Inhibiting Mast Cell Activation - The present invention pertains to the field of prevention and treatment of chronic or acute diseases involving mast cells, such as allergy and some autoimmune diseases. More precisely, the present invention concerns the use of probiotics containing a | 2010-11-11 |
20100284974 | VIRAL CAPSID PROTEINS AND ANY PEPTIDES OR COMPOSITIONS THEREOF FOR THE TREATMENT OF PATHOLOGIC DISORDERS - The present invention relates to viral capsid proteins, as a medicament for the treatment of a pathologic disorder. More particularly, the invention relates to the viral capsid proteins VP1, VP2 and VP3, preferably, the SV40 VP1 or any peptide, fragment, mutant, derivative and mixtures thereof or of virus-like particles (VLP's) comprising the same, as the active ingredient in compositions for the treatment of pathologic disorders, preferably disorders associated with inactivation of cellular proteins involved with quality control processes, particularly, chaperones. The invention further provides methods for the treatment of such disorders and the use of the SV40 capsid proteins for the preparation of pharmaceutical compositions. | 2010-11-11 |
20100284975 | POLYPEPTIDES COMPRISING FAS ACTIVATION AND NKG2D-LIGAND DOMAINS - The present invention is drawn to fusion proteins comprising (a) a ligand for an NK receptor and (b) a Fas activation domain, and to nucleic acids encoding such fusion proteins. The invention also includes methods of making and using such proteins and nucleic acids, including their use in preventing or treating cancer. | 2010-11-11 |
20100284976 | COMPOSITIONS FOR THE PREPARATION OF MATURE DENDRITIC CELLS - The invention relates to a method for in vitro maturation of at least one immature dendritic cell, comprising stimulating said immature dendritic cell with TNFα, IL-1β, IFNγ, a TLR7/8 agonist and prostaglandin E2 (PG). Furthermore, the invention relates to a composition comprising said factors as well as to mature dendritic cells produced by the method of the invention. | 2010-11-11 |
20100284977 | Expression of Anti-Nociceptive Compounds from Endogenously Regulated Promoters - Expression of anti-nociceptive compounds under the control of endogenously regulated promoters is disclosed. Methods and materials can be used to modify nociception, the process activated by detection of noxious stimuli. The activity of endogenous promoters employed is up-regulated following nociception in animal models of pain. Thus, expression of anti-nociceptive compounds, e.g., proteins, antisense RNAs or micro RNAs, under the control of these promoters can occur in an auto-regulatory, demand-driven manner. Delivery to neurons activated during pain transmission of disclosed expression cassettes containing up-regulated promoters to drive expression of anti-nociceptive compounds can be useful for pain management. | 2010-11-11 |
20100284978 | CULTURES, PRODUCTS AND METHODS USING UMBILICAL CORD MATRIX CELLS - Stem cells from human sources can have a variety of useful applications in disease treatment and biotechnology. More particularly the umbilical cord matrix cell cultures of the invention have a variety of totipotent, pluripotent, or multipotent cells for a variety of end uses from a non-controversial, universally available, species-specific source. The technology can have application to any amniotic animal, including agricultural and laboratory animals and humans. The invention relates to isolating the stem cells, culturing the stem cells, maintaining the stem cells, transforming the stem cells into useful cell types using genetic or other transformation technologies, stem cell and tissue banking and using untransformed or transformed cells in disease treatment. | 2010-11-11 |
20100284979 | Modulation of Tissue Fatty Acid Composition of a Host by Human Gut Bacteria - The current invention provides use of a CLA-producing bacterium for the in vivo conversion in the gut of polyunsaturated fatty acids to CLA. The CLA-producing bacterium is selected from one or more of the group consisting of propionibacteria, lactobacilli, lactococci and streptococci, and bifidobacteria. | 2010-11-11 |
20100284980 | Nutritional Composition To Promote Healthy Development And Growth - A nutritional formula which includes a lipid or fat; a protein source; about 5 to about 100 mg/100 kcal of a source of long chain polyunsaturated fatty acids which comprises docosahexanoic acid; about 0.1 to about 1 mg/100 kcal of a prebiotic composition, wherein the prebiotic composition comprises at least 20% of an oligosaccharide which comprises galacto-oligosaccharide; and about 0.015 to about 0.1 (pg/μg) ppm of TGF-β. | 2010-11-11 |
20100284981 | MICROORGANISMS AND METHODS FOR TREATING POULTRY - An isolated | 2010-11-11 |
20100284982 | Erythrocyte-encapsulated L-asparaginase for enhanced acute lymphoblastic leukemia therapy - Compositions for transporting L-asparaginase across the cellular membrane of erythrocytes, comprising a low molecular weight protamine peptide. Process of preparation of compositions comprising conjugates of L-asparaginase and a low molecular weight protamine peptide. Method of treatment comprising administration of adapted L-asparaginase is also described. | 2010-11-11 |
20100284983 | COENZYME Q10-CONTAINING WATER-SOLUBLE COMPOSITION AND PROCESS FOR PRODUCTION THEREOF - A coenzyme Q | 2010-11-11 |
20100284984 | ADENOSINE AND ITS MIMETICS. MODULATORS, TRANSPORT INHIBITORS, AND RECEPTOR AGONISTS AS A THERAPEUTIC TOOL TO REPLACE OR IMPROVE THE EFFICACY OF DEEP BRAIN STIMULATION - The present invention relates to a method of enhancing brain stimulation of a subject. This method involves selecting a subject in need of brain stimulation and electrically stimulating the brain of the subject. Adenosine, an adenosine mimetic, an adenosine modulator, an adenosine transport inhibitor, or an adenosine receptor agonist are administered to the subject under conditions effective to enhance electrical stimulation of the brain of the subject. The administration of adenosine, an adenosine mimetic, an adenosine modulator, an adenosine transport inhibitor, or an adenosine receptor agonist to the subject can alternatively be carried out with electrically stimulating the brain of the subject. | 2010-11-11 |
20100284985 | Composition - The present invention provides a composition comprising (a) an antimicrobial compound of the formula (I) wherein R | 2010-11-11 |
20100284986 | COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF MIGRAINES - A therapeutic composition for preventing migraines is described. The therapeutic composition may include riboflavin, magnesium, feverfew and coenzyme Q10. | 2010-11-11 |
20100284987 | TABLETTABLE FORMULATIONS OF LIPOPHILIC HEALTH INGREDIENTS - The present invention is directed to a formulation of a lipophilic health ingredient comprising a lipophilic health ingredient, a protective colloid comprising a modified starch and an emulsifier. The present invention is further directed to a formulation of (a) lipophilic health ingredient(s) comprising (a) lipophilic health ingredient(s) and a protective colloid, wherein said protective colloid is a modified starch, characterized in that the formulation has a residual moisture content ≦6.5 weight-%, based on the total weight of the formulation, as well as to a process for their manufacture. The latter formulations are especially suitable for the preparation of stable tablets of these lipophilic health ingredients. | 2010-11-11 |
20100284988 | UTILIZATION OF SHIELD EFFECT FOR DOPAMINE DETECTION AND REAGENT DEVELOPMENT - The present invention relates to fusion proteins of monoamine oxidase B (MAO B)-green fluorescent protein (GFP) and utilizes “shield effect” to detect the dopamine under physiological condition, providing the reagent and method for dopamine detection. | 2010-11-11 |
20100284989 | 15-PGDH IN COLON CANCER - The disclosure provides, among other things, a method of decreasing resistance to the chemopreventive properties of non-steroidal anti-inflammatory agents, e.g., celecoxib, particularly in the prevention of cancer, e.g., colon cancer, by increasing the levels or activity of 15-hydroxyprostaglandin dehydrogenase (15-PGDH). The disclosure also provides a method of identifying compounds that upregulate or reactivate 15-PGDH. The disclosure also provides a method of identifying an individual suitable for treatment with a non-steroidal anti-inflammatory agent in the treatment or prevention of colon cancer. | 2010-11-11 |
20100284990 | Compositions and Methods for Making Therapies Delivered by Viral Vectors Reversible for Safety and Allele-Specificity - The present invention is directed to compositions, methods and kits for regulation of gene therapies for Huntington's Disease, including, without limitation, reversible gene therapies and allele-specific therapies. | 2010-11-11 |
20100284991 | Methods for the Treatment and Diagnosis of Bone Mineral Density Related Diseases - The present invention relates to methods of the treatment and diagnosis of bone mineral density related disorders. More particularly, the present invention relates to a method of diagnosing or predicting a bone mineral density related disease, or a risk of a bone mineral density related disease, in a subject, which method comprises detecting a mutation in the TBXAS1 gene, wherein the presence of said mutation is indicative of a bone mineral density related disease or of a risk of a bone mineral density related disease. The invention also relates to a compound selected in the group consisting of a thromboxane synthase (TXAS) encoding polynucleotide, a TXAS, thromboxane A2 or an analog thereof for treating or preventing a disease associated with an increased bone mineral density (e.g., Ghosal hematodiaphyseal dysplasia syndrome). The invention also relates to a compound selected from the group consisting of an inhibitor of TBXAS1 gene expression or a thromboxane inhibitor for treating or preventing a disease associated with a decreased bone mineral density (e.g., osteoporosis). | 2010-11-11 |
20100284992 | Phospholipase C and Method of Use - The present invention provides a method for reducing angiogenesis using a phospholipase C. | 2010-11-11 |
20100284993 | Enhancing the Efficacy of Anti-Infective Therapeutics - In an embodiment of the invention, a method of enhancing the efficacy of an anti-infective therapeutic agent against an obligate or facultative intracellular parasite in a host is provided. The method comprises administering to the host an effective amount of a bifunctional compound of less than about 5000 Daltons comprising the therapeutic or an active derivative, fragment or analog thereof and a protein binding moiety. The protein binding moiety binds to at least one intracellular protein. The bifunctional compound has a higher intracellular concentration as compared to the therapeutic itself in order to enhance the efficacy of the anti-infective therapeutic against the obligate or facultative intracellular parasite. | 2010-11-11 |
20100284994 | USE OF EDTA AND ITS DERIVATIVES FOR PREVENTION AND TREATMENT OF BACTERIAL INTESTINAL DISEASES OF PIGS AND FOR INCREASING THE EFFECTS OF ANTIBIOTICS EXERTED IN SUCH DISEASES - The invention relates to the use of ethylenediamine tetraacetic acid (EDTA) and its derivatives, i.e. its salts and complexes for prevention and treatment of bacterial intestinal diseases of pigs and for increasing the effects of antibiotics exerted in such diseases. The invention also relates to compositions for animal husbandry, i.e. to veterinary compositions and to feeds and drinks which can be consumed by pigs, comprising EDTA or its derivatives. | 2010-11-11 |